Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
DXCM Price Action
Last 7 days
16.8%
Last 30 days
35.2%
Last 90 days
-5.6%
Trailing 12 Months
-35.9%
DXCM Stock Price
DXCM RSI Chart
DXCM Valuation
DXCM Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
DXCM Fundamentals
DXCM Revenue
DXCM Earnings
DXCM Profitability
DXCM Investor Care
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
US
| |||||||||||||||
| |||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 4.1B | 0 | 0 | 0 |
| 2024 | 3.8B | 3.9B | 4.0B | 4.0B |
| 2023 | 3.0B | 3.2B | 3.4B | 3.6B |
| 2022 | 2.6B | 2.7B | 2.8B | 2.9B |
| 2021 | 2.0B | 2.2B | 2.3B | 2.4B |
| 2020 | 1.6B | 1.7B | 1.8B | 1.9B |
| 2019 | 1.1B | 1.2B | 1.4B | 1.5B |
| 2018 | 760.6M | 832.5M | 914.6M | 1.0B |
| 2017 | 599.4M | 632.7M | 668.7M | 718.5M |
| 2016 | 445.4M | 489.8M | 534.2M | 573.3M |
| 2015 | 285.1M | 319.2M | 354.4M | 402.0M |
| 2014 | 177.1M | 200.1M | 226.2M | 259.0M |
| 2013 | 109.5M | 121.8M | 141.6M | 160.0M |
| 2012 | 82.2M | 84.3M | 89.1M | 100.0M |
| 2011 | 53.3M | 62.9M | 69.5M | 76.3M |
| 2010 | 34.4M | 39.2M | 43.9M | 48.6M |
| 2009 | 0 | 0 | 0 | 29.7M |
Get all data in R, Python etc through our Historical Stock Data APIs
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
| CEO | Mr. Kevin Ronald Sayer |
|---|---|
| WEBSITE | dexcom.com |
| SECTOR | Healthcare |
| INDUSTRY | Medical Devices |
| EMPLOYEES | 7500 |
